Search the Newsreel

Voyager Technologies Stock (VOYG) Opinions on BlackRock Stake Increase

Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a beneficial ownership of 7.4% in Voyager Therapeutics (VYGR) common stock through a Schedule 13G/A filing. Integrated Core Strategies (US) LLC also reported a 7.3% stake. The filing clarifies that while …

Operating margin % of Voyager Technologies, Inc. Class A – GETTEX:1QH

This article displays the operating margin percentage for Voyager Technologies, Inc. Class A (GETTEX:1QH) as presented on TradingView. It provides a financial metric for the company but does not include specific values or a detailed analysis. The content primarily serves as a placeholder for …

Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Voyager Therapeutics Inc is projected to report a loss of 48 cents per share in its upcoming earnings. This information is provided as an earnings preview from Refinitiv via Reuters. The full article content is accessible on TradingView.

Voya Financial declares Q3 dividend of $0.47 per share By Investing.com

Voya Financial, Inc. announced a common stock dividend of $0.47 per share for the third quarter of 2026, payable on September 28, 2026, to shareholders of record as of August 26, 2026. The company also declared semi-annual and quarterly dividends for its Series A …

Voya Financial declares common and preferred stock dividends

NEW YORK, July 30, 2026--(BUSINESS WIRE)--Voya Financial, Inc. (NYSE: VOYA) announced today that its board of directors has declared a common stock dividend of $0.47 per share for the third quarter of 2026. The common stock dividend is payable on September 28, 2026, to …

ING4371109 Bond Profile — Key Metrics

This article provides key metrics for the ING4371109 bond, issued by Voya Financial, Inc. The bond has a 4.8% coupon rate and matures on June 15, 2046. It details Voya Financial's business segments, including Retirement, Employee Benefits, and Investment Management.

Voyager Therapeutics Inc (VYGR) Institutional Confidence

Voyager Therapeutics Inc (VYGR) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.36%, marking an 18.22% quarter-over-quarter increase. Key institutional shareholders include Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice …

Earnings Preview: Voya Financial (VOYA) Q2 Earnings Expected to Decline

Voya Financial (VOYA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), outlining major shareholders and institutional holdings. It provides a breakdown of proportional ownership by various entity types and tracks changes in institutional shareholding and individual shareholder activity over recent quarters. The data indicates …

Voyager Technologies, Inc. (VOYG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Voyager Therapeutics Inc (VYGR) Cash Flow

This article provides a detailed cash flow statement for Voyager Therapeutics Inc (VYGR), covering quarterly and annual data for operating, investing, and financing activities. It presents historical financial figures and year-over-year changes for various cash flow components. Additionally, the article includes an FAQ section …

TradingKey

This article provides a detailed quarterly and annual income statement for Voyager Therapeutics Inc. (VYGR), covering financial performance metrics such as total revenue, operating expenses, net income, and earnings per share from FY2014Q1 to FY2026Q1. It also includes FAQs explaining how to interpret the …

Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis

Voyager Therapeutics Inc (VYGR) has a current financial score of 5.98, placing it 303rd out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue was $2.59 million, a 59.94% year-over-year decrease, …

Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR

Voyager Therapeutics, Inc. (NASDAQ: VYGR) generated $40.37 million in revenue last year, with its Genetic Medicine segment being the sole contributor. This marked a decrease from $80.00 million reported in the previous year. The United States was the primary source of revenue for the …

Voyager Technologies, Inc. Class A Revenue Breakdown – DUS:1QH

Voyager Technologies, Inc. (DUS:1QH) generated 141.69 million EUR in revenue last year. The Defense and National Security segment was the top performer, contributing 104.69 million EUR. The United States was the largest geographical contributor, accounting for 128.48 million EUR of the company's revenue.

Voya Financial (VOYA) Stock Looks Reasonable On Earnings But Cheap On Fair Value

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Voya Financial has delivered a 64.8% total return over the past five years, yet the stock still screens as undervalued, with both the Excess Returns intrinsic value …

Voyager Technologies, Inc. Class A (VOYG) Q3 2025 Earnings Report - Results, Call & Slides

Voyager Technologies, Inc. (VOYG) released its Q3 2025 earnings report, showing an actual EPS of -$0.22, beating the consensus estimate of -$0.34 by $0.12. The company missed revenue expectations slightly, reporting $39.59 million against an expected $39.68 million. The next earnings report for VOYG …

Voya Extends Nearly 50-Year Partnership as Retirement Plan Provider with the City and County of Honolulu

WINDSOR, Conn., July 23, 2026--(BUSINESS WIRE)--Voya Financial, Inc. (NYSE: VOYA) announced today it has been selected to continue serving as the provider for the City and County of Honolulu's Deferred Compensation Plan – renewing a relationship built on nearly five decades of trusted service, …

RBC Capital Adjusts Voya Financial PT to $107 From $100, Maintains Outperform Rating

RBC Capital has increased its price target for Voya Financial (NYSE: VOYA) to $107, up from the previous $100, while reaffirming its Outperform rating on the stock. This adjustment reflects continued analyst confidence in the company's financial performance and future prospects.

VOYA Maintained by TD Cowen -- Price Target Raised to $120

TD Cowen has maintained a Buy rating for Voya Financial (VOYA) and increased its price target from $112.00 to $120.00. While the company has a strong GF Score™ of 78/100, indicating potential for long-term returns, GuruFocus deems the stock 19.9% overvalued, with a current …

VOYA Outperforms Industry, Trades Near 52-Week High: Time to Hold?

Shares of Voya Financial, Inc. VOYA have gained 35.7% in the past year, outperforming the industry's growth of 10.8%. The stock closed at $98.25 on Tuesday, near its 52-week high of $103.85, reflecting investor confidence. Growth in the Retirement and Investment Management businesses, improved …

Voyager Technologies, Inc. (VOYG) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed financial information for Voyager Technologies, Inc. (VOYG), including its current stock price, historical data, performance metrics, analyst ratings, and company overview. Voyager Technologies operates in aerospace and defense, offering solutions across defense, space, and commercial space stations with …

H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data

H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ:VYGR) following positive updated preclinical data from its tau-silencing gene therapy program, VY1706. The data showed sustained tau reduction in non-human primates and supported the FDA's clearance of an …

Total assets of Voyager Technologies, Inc. Class A – GETTEX:1QH

This article provides financial data for Voyager Technologies, Inc. Class A (GETTEX:1QH), specifically focusing on its total assets. The information is presented within a TradingView context, showing key financial figures, historical changes, and percentage changes over different periods.

Equity in earnings of Voyager Technologies, Inc. Class A – GETTEX:1QH

This article provides financial information for Voyager Technologies, Inc. Class A, traded on GETTEX under the symbol 1QH. It specifically focuses on the "Equity in earnings" data for the company. The content also notes market status and directs users to additional financial, news, and …

Voyager Therapeutics Q1 2026 Earnings: EPS Beat Narrowly Misses Revenue Visibility as Stock Slips

Voya Equity Closed End Funds Declare Distributions

Voya Investment Management has announced the monthly distributions for five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund, Voya Global Equity Dividend and Premium Opportunity Fund, Voya Infrastructure, Industrials and Materials Fund, Voya Asia Pacific High Dividend Equity Income Fund, and …

VYGR Forecast — Price Target — Prediction for 2027

Voyager Therapeutics (VYGR) Q1 2026 Earnings: EPS Beat of 16.4% Amid Continued Pipeline Progress - Guidance vs Actual

Is Voyager Technologies, Inc. (VOYG) A Good Stock To Buy Now?

VOYG Stock Climbs As Voyager Lifts 2026 Space Revenue Outlook

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

Analysts Are Updating Their Voyager Technologies, Inc. (NYSE:VOYG) Estimates After Its First-Quarter Results

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky